Graphite Bio, Inc. – NASDAQ:GRPH
Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 8 hours
Graphite Bio stock price monthly change
+8.39%
month
Graphite Bio stock price quarterly change
+26.92%
quarter
Graphite Bio stock price yearly change
+32.59%
year
Graphite Bio key metrics
Market Cap | 185.19M |
Enterprise value | N/A |
P/E | -0.12 |
EV/Sales | -1.46 |
EV/EBITDA | 0.99 |
Price/Sales | 18.09 |
Price/Book | 0.07 |
PEG ratio | N/A |
EPS | -15.87 |
Revenue | N/A |
EBITDA | -38.49M |
Income | -117.36M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -1146.59% |
Oper. margin | -1112.5% |
Gross margin | 70.3% |
EBIT margin | -1112.5% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGraphite Bio stock price history
Graphite Bio stock forecast
Graphite Bio financial statements
| Jun 2023 | 0 | -55.31M | |
|---|---|---|---|
| Sep 2023 | 0 | -22.48M | |
| Dec 2023 | 10.23M | -22.91M | -223.9% |
| Mar 2024 | 0 | -16.64M |
| 2027 | 0 | -3.25M |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-05-11 | -0.3 | -0.38 |
|---|---|---|
| 2023-08-14 | -0.31 | -0.31 |
| 2023-11-13 | -0.25 | -0.19 |
| 2024-03-25 | -0.13 | -0.4 |
| Jun 2023 | 287044000 | 62.89M | 21.91% |
|---|---|---|---|
| Sep 2023 | 266228000 | 62.20M | 23.37% |
| Dec 2023 | 188456000 | 4.87M | 2.59% |
| Mar 2024 | 217322000 | 19.15M | 8.81% |
| Jun 2023 | -13.65M | 72.22M | 124K |
|---|---|---|---|
| Sep 2023 | -9.40M | 63.87M | 8K |
| Dec 2023 | -45.87M | 47.08M | 66K |
| Mar 2024 | -23.93M | 18M | 171.26M |
Graphite Bio alternative data
| Aug 2023 | 120 |
|---|---|
| Sep 2023 | 120 |
| Oct 2023 | 120 |
| Nov 2023 | 120 |
| Dec 2023 | 120 |
| Jan 2024 | 120 |
| Feb 2024 | 120 |
| Mar 2024 | 6 |
| Apr 2024 | 6 |
| May 2024 | 6 |
| Jun 2024 | 6 |
| Jul 2024 | 6 |
Graphite Bio other data
7.90%
-44.24%
of GRPH is owned by hedge funds
28
-34
4.33M
-24.45M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2021 | 865882 | 0 |
| Oct 2021 | 196296 | 0 |
| Nov 2021 | 201685 | 0 |
| Dec 2021 | 22329 | 0 |
| Jan 2022 | 220670 | 0 |
| Apr 2022 | 429464 | 0 |
| Insider | Compensation |
|---|---|
Dr. Joshua Lehrer-Graiwer FACC, M.D. (1974) Pres, Chief Executive Officer & Director | $561,280 |
Mr. Philip P. Gutry (1973) Chief Bus. Officer, Head of Fin. & Investor Relations | $170,450 |
Dr. Matthew Porteus M.D., Ph.D. (1965) Academic Founder & Director | $53,850 |
| Dr. Maria Grazia Roncarolo M.D., Ph.D. (1954) Academic Founder | $53,650 |
Biopharmaceutical Stocks Continue To Perform Well, With Many Attractive Values Remaining
Healthcare Sector Stock Performance Continues To Improve
Graphite Bio: Selling For Much Less Than Net Cash
Graphite Bio: An Important Stock To Track In The Gene Editing Space
Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile
-
When is Graphite Bio's next earnings date?
Unfortunately, Graphite Bio's (GRPH) next earnings date is currently unknown.
-
Does Graphite Bio pay dividends?
Yes, Graphite Bio pays dividends and its trailing 12-month yield is 64.78% with 0% payout ratio. The last Graphite Bio stock dividend of undefined was paid on 25 Sep 2025.
-
How much money does Graphite Bio make?
Graphite Bio has a market capitalization of 185.19M. Graphite Bio made a loss 124.65M US dollars in net income (profit) last year or -$0.4 on an earnings per share basis.
-
What is Graphite Bio's stock symbol?
Graphite Bio, Inc. is traded on the NASDAQ under the ticker symbol "GRPH".
-
What is Graphite Bio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Graphite Bio?
Shares of Graphite Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Graphite Bio's key executives?
Graphite Bio's management team includes the following people:
- Dr. Joshua Lehrer-Graiwer FACC, M.D. Pres, Chief Executive Officer & Director(age: 51, pay: $561,280)
- Mr. Philip P. Gutry Chief Bus. Officer, Head of Fin. & Investor Relations(age: 52, pay: $170,450)
- Dr. Matthew Porteus M.D., Ph.D. Academic Founder & Director(age: 60, pay: $53,850)
- Dr. Maria Grazia Roncarolo M.D., Ph.D. Academic Founder(age: 71, pay: $53,650)
-
Is Graphite Bio founder-led company?
Yes, Graphite Bio is a company led by its founders Dr. Matthew Porteus M.D., Ph.D. and Dr. Maria Grazia Roncarolo M.D., Ph.D..
-
How many employees does Graphite Bio have?
As Jul 2024, Graphite Bio employs 6 workers.
-
When Graphite Bio went public?
Graphite Bio, Inc. is publicly traded company for more then 4 years since IPO on 25 Jun 2021.
-
What is Graphite Bio's official website?
The official website for Graphite Bio is graphitebio.com.
-
Where are Graphite Bio's headquarters?
Graphite Bio is headquartered at 201 Haskins Way, South San Francisco, CA.
-
How can i contact Graphite Bio?
Graphite Bio's mailing address is 201 Haskins Way, South San Francisco, CA and company can be reached via phone at +65 04840886.
Graphite Bio company profile:
Graphite Bio, Inc.
graphitebio.comExchange:
NASDAQ
Full time employees:
6
Industry:
Biotechnology
Sector:
Healthcare
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
201 Haskins Way
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001815776
ISIN: US38870X1046
CUSIP: 38870X104
